Tonix Pharmaceuticals stock halted ahead of FDA approval news
LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF), known for its work on gene therapies aimed at decelerating aging, has disclosed a significant share purchase by its CEO, Dr. Eric Leire. On Monday, Dr. Leire acquired 2,100,000 ordinary shares of the company at a price of 1.15 pence each, totaling a transaction value of £24,150. This market purchase increases his total shareholding to 126,514,999, representing an interest of 36.18% in the company.
The transaction, which took place in London, was conducted in accordance with the UK Market Abuse Regulation. Genflow Biosciences, which was founded in 2020 and operates out of the UK with R&D facilities in Belgium, focuses on developing gene therapies that could potentially extend human life spans by targeting the aging process. The company’s lead compound, GF-1002, is designed to deliver a centenarian variant of the SIRT6 gene, which has shown encouraging results in preclinical trials.
Genflow is preparing to initiate clinical trials in 2025 to evaluate the efficacy of GF-1002 in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a common chronic liver disease currently lacking effective treatments.
The information regarding this director’s dealing has been made public in line with regulatory requirements and is now in the public domain. The details of the transaction underline the CEO’s increased investment in the company, which may be of interest to current and potential shareholders, reflecting a tangible commitment to the firm’s future.
This news article is based on a press release statement provided by Genflow Biosciences Plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.